Purple Biotech (PPBT) Expected to Release Earnings on Friday

Purple Biotech (NASDAQ:PPBT) will likely be issuing its results before the market opens on Friday, November 13th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.

Purple Biotech Price Performance

PPBT opened at $1.34 on Wednesday. The company has a market capitalization of $1.25 million, a PE ratio of -0.06 and a beta of 0.77. The firm has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $2.86. Purple Biotech has a 52 week low of $0.91 and a 52 week high of $8.90.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $30.00.

Purple Biotech Company Profile

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.